Lionel Van Holle

Lionel Van Holle

Auto-generated profile, based on publicly available information

Lionel Van Holle

GlaxoSmithKline Biologicals SA Wavre Belgium

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2016 in Drug Safety
Verified
Journal Article
Open access
PDF file
AWAntoni F. Z. Wisniewski
Antoni F. Z. Wisniewski
ABAndrew Bate
Andrew Bate
CBCedric Bousquet
Cedric Bousquet
ABAndreas Brueckner
Andreas Brueckner
GCGianmario Candore
Gianmario Candore
GNG. Niklas Norén
G. Niklas Norén
Over a period of 5 years, the Innovative Medicines Initiative PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) project has addressed key research questions relevant to the science of safety signal detection. The results of studies conducted into quantitative signal detection in spontaneous reporting, clinical trial and electronic health records databases are summarised and 39 recommendations have been formulated, many based on comparative analyses across a range of databases (e.g. regulatory, pharmaceutical company). The recommendations point to pragmatic steps that those working in the pharmacovigilance community can take to improve signal detection practices, whether in a national or international agency or in a pharmaceutical company setting. PROTECT has also pointed to areas of potentially fruitful future research and some areas where further effort is likely to yield less.

25 November 2015 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
OMOlivia Mahaux
Olivia Mahaux
VBVincent Bauchau
Vincent Bauchau
LHLionel Van Holle
Lionel Van Holle
Keywords: Observed-to-expected; pharmacoepidemiology; methodology; uncertainty analyses; pharmacoepidemiology

15 November 2013 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
FMFrancois Maignen
Francois Maignen
MHManfred Hauben
Manfred Hauben
EHEric Hung
Eric Hung
LHLionel Van Holle
Lionel Van Holle
JDJean‐Michel Dogne
Jean‐Michel Dogne

1 March 2012 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
LHLionel Van Holle
Lionel Van Holle
ZZZiad Zeinoun
Ziad Zeinoun
VBVincent Bauchau
Vincent Bauchau
TVThomas Verstraeten
Thomas Verstraeten

1 April 2020 in Vaccine
Verified
Journal Article
Open access
FTFernanda Tavares
Fernanda Tavares
MCMaribel Miranda Co
Maribel Miranda Co
CDChristophe Dessart
Christophe Dessart
CHCaroline Hervé
Caroline Hervé
MLMarta López-Fauqued
Marta López-Fauqued
JSJens-Ulrich Stegmann
Jens-Ulrich Stegmann
The adjuvanted recombinant zoster vaccine (RZV) received its first marketing authorization in October 2017, for prevention of herpes zoster in individuals aged ≥50 years. We summarized safety information, following RZV administration, received by GSK via spontaneous adverse event (AE) reports submitted by healthcare providers, vaccine recipients and other reporters. Observed-to-expected (O/E) analyses were performed for selected outcomes: reports of death, Guillain-Barré syndrome and Bell's palsy. Standard case definitions were used to assess individual case reports. Data mining, using proportional reporting ratio and time-to-onset signal detection methods, was employed to identify RZV-AE pairs with disproportionate reporting or unexpected time-to-onset distribution. Between October 13, 2017 and February 10, 2019, an estimated 9.3 million doses were distributed and GSK received 15,638 spontaneous AE reports involving RZV. Most reports were classified as non-serious (95.3%) and originated from the United States (81.7%), where the majority of doses were distributed. Among reports with age or sex reported, individuals were mainly 50-69-year-olds (62.1%) and female (66.7%). Of all reports, 3,579 (22.9%) described vaccination errors, of which 82.7% were without associated symptoms. Of all vaccination error reports, most described errors of vaccine preparation and reconstitution (29.7%), inappropriate schedule or incomplete course of administration (26.7%), incorrect route of administration (16.4%), and storage errors (12.9%). The most commonly reported symptoms were consistent with the known RZV reactogenicity profile observed in clinical trials, including injection site reactions, pyrexia, chills, fatigue, headache. O/E analyses for selected outcomes and data mining analyses for all reported AEs did not identify any unexpected patterns. Review of the initial data from the post-marketing safety surveillance showed that the safety profile of RZV is consistent with that previously observed in pre-licensure clinical trials. Other studies are ongoing and planned, to continue generating real-world safety data and further characterize RZV.

15 November 2013 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
FMFrancois Maignen
Francois Maignen
MHManfred Hauben
Manfred Hauben
EHEric Hung
Eric Hung
LHLionel Van Holle
Lionel Van Holle
JDJean‐Michel Dogne
Jean‐Michel Dogne